Bilateral ocular panadnexal mass as initial presentation of systemic blastoid variant of mantle-cell lymphoma.

Surv Ophthalmol

Department of Ophthalmology, Faculty of Medicine, University of Belgrade, Serbia; Department of Ocular and Ocular Adnexal tumors, Orbital and Lacrimal System Pathology, and Ocular Oncology, Clinic of Eye Diseases, Clinical Center of Serbia, Belgrade, Serbia.

Published: May 2017

A 66-year-old man developed a slowly enlarging, bilateral, painless, periorbital, and orbital swelling with ptosis, nonaxial proptosis, chemosis, exposure keratopathy, and decreased vision in both eyes. He had fever, night sweats, and weight loss (B-symptoms), along with lymphadenopathy and elevated serum lactate dehydrogenase, with no prior history of lymphoma. A transpalpebral incisional biopsy revealed a rare case of mantle-cell lymphoma of blastoid variant, stage IVB. The main immunophenotype characteristics were cyclin D1+, CD5+, CD10-, CD23-, Bcl-6-/+, and a high (up to 80%) Ki-67 proliferation index. Following an excellent response to the immune-chemotherapy treatment plan, all ocular adnexal lymphoma manifestations disappeared completely; however, 13 months after the initial presentation, there was a recurrence of the disease with rapid worsening and death. The blastoid variant of mantle cell lymphoma, a rare subtype of mantle-cell lymphoma, is a highly aggressive neoplasm, ultimately having a fatal outcome. As the initial manifestation of the disease, ocular adnexal region blastoid variant of mantle-cell lymphoma is an exceptional event, with only one previous case reported.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.survophthal.2016.05.005DOI Listing

Publication Analysis

Top Keywords

blastoid variant
16
mantle-cell lymphoma
16
initial presentation
8
variant mantle-cell
8
ocular adnexal
8
lymphoma
7
bilateral ocular
4
ocular panadnexal
4
panadnexal mass
4
mass initial
4

Similar Publications

Brexucabtagene autoleucel (brexu-cel) has revolutionized the treatment of patients affected by mantle cell lymphomas. In this prospective, observational multicentre study, we evaluated 106 patients, with longitudinal brexu-cel kinetics in peripheral blood monitored in 61 of them. Clinical outcomes and toxicities are consistent with previous real-world evidence studies.

View Article and Find Full Text PDF

A rapid progression from classical mantle cell lymphoma to a blastoid variant.

Leuk Res Rep

November 2024

Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Laboratoire d'hématologie biologique, Pierre-Bénite, France.

This case report presents an 82-year-old male initially diagnosed with classical mantle cell lymphoma (MCL) that progressed to the aggressive blastoid variant. The patient was initially treated with oral chemotherapy (PEP-C), followed by ibrutinib, but experienced disease progression with central nervous system (CNS) involvement and blastoid morphology. Despite subsequent intensive treatment, including high-dose cytarabine (Cytarabine), rituximab, and intrathecal methotrexate (Methotrexate), the patient's disease continued to advance, resulting in death.

View Article and Find Full Text PDF
Article Synopsis
  • Blastoid variant-mantle cell lymphoma (BV-MCL) is a serious condition with no standard treatment, prompting a study of 17 patients at a medical institution from 2009 to 2023.
  • The study found that the overall response to initial treatment was 66.7%, but the overall survival rate after two years was only 62.5%, influenced by factors like type of therapy and genetic variations.
  • New BTK inhibitor therapies show promise for improving outcomes in these high-risk patients, especially for those without TP53 mutations.
View Article and Find Full Text PDF

Mantle cell lymphoma (MCL) is a type of lymphoid malignancy that is rare in Japan. MCL is refractory to conventional chemotherapy and has dismal outcomes. Nonetheless, the prognosis of MCL has gradually improved with the advent of autologous stem cell transplantation and BTK inhibitors.

View Article and Find Full Text PDF

The patient we present here had many clinical, morphological, and laboratory findings characteristic of acute leukemia. During the course of the disease, the diagnosis changed from acute leukemia to chronic small B-cell lymphoproliferative disease, a blastoid variant of mantle cell lymphoma, and finally to atypical plasma cell leukemia. Atypical plasma cell leukemia is a rare condition with aggressive biological behavior.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!